242 related articles for article (PubMed ID: 27349451)
21. Preface.
Prudhomme M
Anticancer Agents Med Chem; 2017; 17(1):3. PubMed ID: 28143384
[No Abstract] [Full Text] [Related]
22. Topoisomerase IIα poisoning and DNA double-strand breaking by chiral ruthenium(ii) complexes containing 2-furanyl-imidazo[4,5-f][1,10]phenanthroline derivatives.
Qian C; Wu J; Ji L; Chao H
Dalton Trans; 2016 Jun; 45(26):10546-55. PubMed ID: 27226117
[TBL] [Abstract][Full Text] [Related]
23. Ruthenium-arene complexes bearing naphthyl-substituted 1,3-dioxoindan-2-carboxamides ligands for G-quadruplex DNA recognition.
Hager LA; Mokesch S; Kieler C; Alonso-de Castro S; Baier D; Roller A; Kandioller W; Keppler BK; Berger W; Salassa L; Terenzi A
Dalton Trans; 2019 Aug; 48(32):12040-12049. PubMed ID: 31292575
[TBL] [Abstract][Full Text] [Related]
24. Strained ruthenium complexes are potent light-activated anticancer agents.
Howerton BS; Heidary DK; Glazer EC
J Am Chem Soc; 2012 May; 134(20):8324-7. PubMed ID: 22553960
[TBL] [Abstract][Full Text] [Related]
25. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, characterization and anticancer mechanism studies of fluorinated cyclometalated ruthenium(ii) complexes.
Wen Y; Ouyang C; Li Q; Rees TW; Qiu K; Ji L; Chao H
Dalton Trans; 2020 Jun; 49(21):7044-7052. PubMed ID: 32406463
[TBL] [Abstract][Full Text] [Related]
27. Induction of the Endoplasmic Reticulum Stress Pathway by Highly Cytotoxic Organoruthenium Schiff-Base Complexes.
Chow MJ; Babak MV; Tan KW; Cheong MC; Pastorin G; Gaiddon C; Ang WH
Mol Pharm; 2018 Aug; 15(8):3020-3031. PubMed ID: 29979603
[TBL] [Abstract][Full Text] [Related]
28. Ruthenium(II) polypyridyl complexes: cellular uptake, cell image and apoptosis of HeLa cancer cells induced by double targets.
Yu Q; Liu Y; Xu L; Zheng C; Le F; Qin X; Liu Y; Liu J
Eur J Med Chem; 2014 Jul; 82():82-95. PubMed ID: 24878637
[TBL] [Abstract][Full Text] [Related]
29. Cyclometalated Ruthenium(II) Anthraquinone Complexes Exhibit Strong Anticancer Activity in Hypoxic Tumor Cells.
Zeng L; Chen Y; Huang H; Wang J; Zhao D; Ji L; Chao H
Chemistry; 2015 Oct; 21(43):15308-19. PubMed ID: 26338207
[TBL] [Abstract][Full Text] [Related]
30. cis-[RuCl(BzCN)(bipy)(dppe)]PF6 induces anti-angiogenesis and apoptosis by a mechanism of caspase-dependent involving DNA damage, PARP activation, and Tp53 induction in Ehrlich tumor cells.
Magalhães LF; Mello-Andrade F; Pires WC; Silva HD; da Silva PFF; Macedo LM; Henrique de Castro C; Carneiro CC; Cardoso CG; de Melo Reis PR; Camargo de Oliveira L; Caetano RR; Batista AA; Silveira-Lacerda EP
Chem Biol Interact; 2017 Dec; 278():101-113. PubMed ID: 28935426
[TBL] [Abstract][Full Text] [Related]
31. Anticancer metallodrugs: where is the next cisplatin?
Hanif M; Hartinger CG
Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
[TBL] [Abstract][Full Text] [Related]
32. Modulating the Anticancer Activity of Ruthenium(II)-Arene Complexes.
Clavel CM; Păunescu E; Nowak-Sliwinska P; Griffioen AW; Scopelliti R; Dyson PJ
J Med Chem; 2015 Apr; 58(8):3356-65. PubMed ID: 25812075
[TBL] [Abstract][Full Text] [Related]
33. Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
Novak MS; Büchel GE; Keppler BK; Jakupec MA
J Biol Inorg Chem; 2016 Jun; 21(3):347-56. PubMed ID: 26961253
[TBL] [Abstract][Full Text] [Related]
34. On the antitumor properties of novel cyclometalated benzimidazole Ru(II), Ir(III) and Rh(III) complexes.
Yellol GS; Donaire A; Yellol JG; Vasylyeva V; Janiak C; Ruiz J
Chem Commun (Camb); 2013 Dec; 49(98):11533-5. PubMed ID: 24177492
[TBL] [Abstract][Full Text] [Related]
35. A Review of Ruthenium Complexes Activities on Breast Cancer Cells.
Popolin CP; Cominetti MR
Mini Rev Med Chem; 2017; 17(15):1435-1441. PubMed ID: 28176627
[TBL] [Abstract][Full Text] [Related]
36. Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole-Containing Ruthenium Complexes.
Liu P; Jia J; Zhao Y; Wang KZ
Mini Rev Med Chem; 2016; 16(4):272-89. PubMed ID: 26586123
[TBL] [Abstract][Full Text] [Related]
37. Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.
Notaro A; Gasser G
Chem Soc Rev; 2017 Nov; 46(23):7317-7337. PubMed ID: 29027562
[TBL] [Abstract][Full Text] [Related]
38. Serendipitous Synthesis of Five-Coordinated Half-Sandwich Aminoimine Iridium(III) and Ruthenium(II) Complexes and Their Application as Potent Anticancer Agents.
Du Q; Guo L; Ge X; Zhao L; Tian Z; Liu X; Zhang F; Liu Z
Inorg Chem; 2019 May; 58(9):5956-5965. PubMed ID: 30986046
[TBL] [Abstract][Full Text] [Related]
39. Polypyridyl Ruthenium(II) complex-induced mitochondrial membrane potential dissipation activates DNA damage-mediated apoptosis to inhibit liver cancer.
Li Y; Wu Q; Yu G; Li L; Zhao X; Huang X; Mei W
Eur J Med Chem; 2019 Feb; 164():282-291. PubMed ID: 30599417
[TBL] [Abstract][Full Text] [Related]
40. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
Lazarević T; Rilak A; Bugarčić ŽD
Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
